Insider buying last 90 days
No open-market insider purchases were filed for QGEN in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every QGEN insider filing, plotted on the chart in Gekko.Open QGEN in Gekko
NYSE: QGEN
Qiagen (QGEN) Stock Analysis & Forecast
Sep 28 close
$45.01+0.83 (+1.9%)
Gekko Brief
AI summaryQiagen this week completes its U.S. QIAstat-Dx bloodstream infection portfolio with FDA clearance of a new panel for detecting gram-negative bacteria and antibiotic resistance markers, and launches QIAmini, a compact automated system for small-batch sample preparation that cuts hands-on time by over 80%. Deutsche Bank's Jan Koch reiterates a Buy rating with a target price of EUR 47, while a separate report cites a consensus "Hold" rating from 14 brokerages and a 12-month price target of $43.51, noting the company recently exceeded quarterly earnings and revenue expectations with $0.62 per share on $535.04 million in revenue. The Dutch AFM also disclosed a BlackRock stake of 11.42% capital interest and 12.83% voting rights in Qiagen.
QGEN closes at $45.01, up 1.9%, sitting above both its 50-day average of $42.83 and 200-day average of $42.68, with the 50-day above the 200-day. The GekkoIndex reads 51.4, placing the stock in the Neutral zone. Price stands 6.2% below Gekko Fair Value of $48.00.
Qiagen's next earnings report is scheduled for 3 November 2026, 35 days out and beyond a typical 20-trading-day holding window; the prior quarter saw EPS of $0.54 match the $0.54 estimate with a reaction of -1.4%. No insider, Congress or unusual options activity appears in their respective windows, though one trailblazer holder is noted. Seasonally, the next 20 trading days have averaged 0.1% over five years, rising in 3 of them.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Qiagen price vs fair value
Close $45.01200-day averageGekko Fair Value $48.00
Qiagen quick facts
- Market cap
- $9.28B
- P/E ratio
- 22.2
- Forward P/E
- 13.5
- EPS, TTM
- $2.01
- Revenue, TTM
- $2.10B
- Profit margin
- 19.5%
- Dividend yield
- 0.83%
- Beta
- 0.63
- Volume
- 2.75M avg 1.77M
- 1-year return
- +2.5%
- Typical daily move
- ±2.5%
- Typical 20-day move
- ±4.4%
- 50-day average
- $42.83
- 200-day average
- $42.68
- Next earnings
- Nov 3
- Shares outstanding
- 206.5M
Qiagen swing-trade checklist
Qiagen scores 4 supportive, 1 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive1 mixed0 headwinds
- Trendsupportive
Above 50 and 200-day
Close $45.01 is above the 50-day ($42.83) and 200-day ($42.68) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
51.4, Neutral
Reading 51.4 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
6.2% below
Price is 6.2% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 35 days
Next report Nov 3, 2026, 35 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+0.1% on average
From this point in the calendar, the next 20 trading days averaged +0.1% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Qiagen stock chart and price history
Qiagen closed at $45.01 on Sep 28, 2026, +2.5% over the past year, inside a 52-week range of $32.53 to $57.82.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +2.9%
- 3 months
- +13.1%
- 6 months
- +15.2%
- 1 year
- +2.5%
The full QGEN chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open QGEN in Gekko
Follow Qiagen through every session
Put QGEN on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track QGEN in GekkoFree for 7 days. No credit card required.
About Qiagen
Qiagen focuses on converting raw biological specimens into readable molecular information for laboratories worldwide. It is known for kits and devices that isolate and purify DNA and RNA from samples, plus diagnostic consumables used in tuberculosis screening, monitoring transplant patients, prenatal checks, and identifying HPV and other sexually transmitted infections. Its catalog also includes PCR-based research products, tools for human identification and forensic work, and next-generation sequencing items like gene panels and library preparation reagents.
The business is built around three pillars: disposable consumables, laboratory instruments, and digital tools, giving customers both the reagents and the hardware needed to run tests, plus bioinformatics platforms and cloud-based software for analyzing outcomes. Buyers include diagnostic labs and life sciences researchers working across genomics, infectious disease detection, and forensic genealogy applications.
Qiagen traces back to 1984 and operates out of Venlo in the Netherlands. Its stock trades on the NYSE under the ticker QGEN.
- Listed
- NYSE
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- qiagen.com
Qiagen GekkoIndex: the smart money zone
Qiagen’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 51.4, in the Neutral zone, down 1.9 points over five sessions.
51.4Neutral
Down 1.9 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 65 | −0.6% | +2.9% | ||
| Accumulation | 205 | 0.0% | −0.7% | ||
| Neutral (current zone) | 378 | +0.4% | +0.7% | ||
| Distribution | 23 | −3.0% | −5.6% | ||
| Selling | 1 | Too few readings yet | |||
Average QGEN share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the QGEN price, zone by zone.Track QGEN in Gekko
Is Qiagen stock overvalued? Gekko Fair Value
Qiagen trades 6.2% below Gekko Fair Value of $48.00, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Qiagen shares are worth, recalculated every trading day.
$48.00
Gekko Fair Value, Sep 26, 2026
6.2% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open QGEN in Gekko
Qiagen insider and Congress trading
No open-market insider purchases were filed for Qiagen, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in QGEN were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for QGEN, plotted on the chart in Gekko.Open QGEN in Gekko
Buybacks
Qiagen has been buying back its own shares.
- Bought back, quarter ended Mar 31, 2026
- $496.7M
- As a share of market cap
- 5.35%
- Trailing four quarters
- $519.1M
From company filings.
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds QGEN.
1added0opened0trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Qiagen earnings: next date and track record
Qiagen reports on Nov 3, 2026 (35 days away), and beat the EPS estimate in 3 of its last 8 reports.
Next earnings report
Nov 3, 2026
35 days away
- EPS estimate
- $0.62
- Revenue estimate
- $535.9M
3 of 8reports beat the EPS estimate
±2.1%average move across the report
2 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| May 6, 2026 | $0.54 est $0.54 | $492.3M est $496.1M | −1.4% |
| Feb 4, 2026 | $0.62 est $0.61 | $540.4M est $528.4M | −1.3% |
| Nov 4, 2025 | $0.64 est $0.61 | $532.6M est $525.9M | −3.6% |
| Aug 5, 2025 | $0.60 est $0.60 | $533.5M est $515.8M | −5.5% |
| May 7, 2025 | $0.55 est $0.50 | $483.5M est $468.9M | 0.0% |
| Feb 5, 2025 | $0.64 est $0.65 | $521.2M est $518.5M | −2.1% |
| Nov 6, 2024 | $0.48 est $0.52 | $502.6M est $491.7M | +0.4% |
| Jul 31, 2024 | −$0.90 est $0.48 | $496.3M est $491.7M | +2.4% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Qiagen stock forecast and analyst price targets
Analysts’ average 12-month price target for Qiagen is $46.27, +2.8% from the last close, from 12 firms rating the stock in the last 90 days.
$46.27consensus 12-month target, +2.8% from the last close
Now $45.01Avg $46.27
Low $40High $53.46
Each firm’s latest rating in the last 90 days: 12 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 24 | Deutsche Bank | $53.46 | +18.8% |
| Sep 11 | Morgan Stanley | $48.66 | +8.1% |
| Sep 10 | Berenberg Bank | $45.50 | +1.1% |
| Sep 9 | UBS | $47 | +4.4% |
| Aug 24 | William Blair | — | — |
+0.7%average 20-day move after past Neutral readings
+0.1%average move over the next 20 trading days in the last 5 years
±2.5%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Qiagen seasonality: the next 20 trading days
Over the next 20 trading days from Sep 29, Qiagen averaged +0.1% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +1.8% | 3 of 5 |
| Next 10 trading days | +1.0% | 2 of 5 |
| Next 15 trading days | +0.9% | 3 of 5 |
| Next 20 trading days | +0.1% | 3 of 5 |
| Next 30 trading days | +1.1% | 2 of 5 |
For scale, QGEN’s typical 20-trading-day move in either direction is about 4.4%.
Qiagen market cap and key statistics
Qiagen’s market cap is $9.28B, with a P/E ratio of 22.2 and revenue of $2.10B over the last twelve months.
Valuation
- Market cap
- $9.28B
- P/E ratio
- 22.2
- Forward P/E
- 13.5
- EPS, TTM
- $2.01
- Gekko Fair Value
- $48.00
Trading
- Volume
- 2.75M
- Avg volume, 20 days
- 1.77M
- 52-week high
- $57.82
- 52-week low
- $32.53
- Shares outstanding
- 206.5M
Financials
- Revenue, TTM
- $2.10B
- Profit margin
- 19.5%
- Return on equity
- 11.9%
- Quarterly earnings growth, YoY
- +7.9%
Risk and income
- Beta
- 0.63
- Typical daily move
- ±2.5%
- Typical 20-day move
- ±4.4%
- Dividend yield
- 0.83%
Qiagen stock news this week
Coverage of Qiagen this week reads neutral: 8 positive, 10 neutral and 0 negative headlines.
- QIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection PanelBioSpace, Sep 28
- Qiagen N.V. (NYSE:QGEN) Stock Has Consensus Target Price of $43.51MarketBeat, Sep 26
- Qiagen N.V. (QGEN) Stock Price, News, Quote & HistoryYahoo! Finance Canada, Sep 26
- Warren Wise decodes Qiagen’s DNATradingView, Sep 25
- Qiagen N.V. $QGEN Holdings Raised by State Street CorpMarketBeat, Sep 25
- QIAGEN Launches QIAmini to Automate Small-Batch Sample PreparationYahoo! Finance Canada, Sep 24
Qiagen peers
Qiagen’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Distribution | 23.7% above |
| ABTAbbott Laboratories | Accumulation | 15.0% below |
| DHRDanaher | Distribution | 10.2% above |
| ISRGIntuitive Surgical | Neutral | 17.0% above |
| MDTMedtronic | Accumulation | 24.1% below |
| SYKStryker | Accumulation | 14.1% below |
A peer links to its own page where one exists.
Qiagen stock FAQ
What is Qiagen’s market cap?
Qiagen’s market cap is $9.28B at the Sep 28, 2026 close of $45.01, with 206.5M shares outstanding. The shares trade on a P/E ratio of 22.2.
What is the Qiagen stock forecast?
The consensus analyst 12-month price target for Qiagen is $46.27, +2.8% from the last close. Of the 12 firms that rated the stock in the last 90 days, 5 rate it a buy, 7 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Qiagen stock overvalued or undervalued?
On Gekko’s estimate Qiagen is undervalued: the Sep 28, 2026 close of $45.01 is 6.2% below Gekko Fair Value of $48.00. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Qiagen report earnings next?
Qiagen is expected to report on Nov 3, 2026 (35 days away). Analysts expect earnings of $0.62 per share on revenue of $535.9M. Qiagen beat the earnings estimate in 3 of its last 8 reports, moving 2.1% on average across the report.
What is Qiagen’s 52-week high and low?
Qiagen’s 52-week high is $57.82 and its 52-week low is $32.53; it closed at $45.01 on Sep 28, 2026, +2.5% over the past year. Over the last five years the shares peaked at $58.43 on Nov 26, 2021.
Is Qiagen stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 5 items with data read as supportive (trend, fair value, earnings risk and seasonality), 1 as mixed (gekkoindex). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Qiagen the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.